ACER
Acer Therapeutics Inc

Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); emetine hydrochloride, a host-directed therapy against a variety of infectious diseases, initially for the treatment of patients with COVID-19; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer's product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
Market Cap: 37.6 Million
Primary Exchange: NASDAQ
Website: acertx.com
Shares Outstanding: 15.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.780420498252356
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags

Longest drawdown: 2777 trading days
From: 2013-02-05 To: 2023-01-27
Lowest Point:
Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date
via: SeekingAlpha at 2019-06-11 12:00:30:000
Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...
Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date
via: SeekingAlpha at 2019-06-11 12:00:30:000
Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...
Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date
via: SeekingAlpha at 2019-06-11 12:00:30:000
Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|---|---|---|---|---|---|
2017-09-21 | 10.355527 | 1.0 | 10.355527 | |||
2015-09-29 | 8.0 | 1.0 | 8.0 |